Spencer Trask & Co. announced the launch of Signal12, a clinical-stage dry eye company that plans to advance Pro-ocular for the treatment of dry eye disease, according to a press release.
Pro-ocular, licensed from Glia LLC, uses transappendageal forehead delivery to treat dry eye disease by targeting the ophthalmic branch of the trigeminal nerve, according to the release. Twice-daily application to the forehead may eliminate the need for eye drops.
The treatment previously demonstrated safety and effectively reduced signs and symptoms of dry eye disease in three phase 2 clinical studies.